# Study of VX-770 and Rifampin in Healthy Male Subjects

> **NCT01018368** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 24 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-770
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01018368
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018368, "Study of VX-770 and Rifampin in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01018368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*